Working… Menu

To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04500132
Recruitment Status : Recruiting
First Posted : August 5, 2020
Last Update Posted : August 6, 2020
Information provided by (Responsible Party):
Enzychem Lifesciences Corporation

Brief Summary:
Prevention of COVID-19 infection to severe pneumonea or ARDS

Condition or disease Intervention/treatment Phase
COVID-19 Drug: EC-18 Drug: Placebo EC-18 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Phase 2, Multi-center, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia
Actual Study Start Date : May 28, 2020
Estimated Primary Completion Date : August 2021
Estimated Study Completion Date : May 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pneumonia

Arm Intervention/treatment
Experimental: EC-18 Arm
EC-18 QD
Drug: EC-18
EC-18 QD

Placebo Comparator: Placebo Arm
Placebo EC-18 QD
Drug: Placebo EC-18
Placebo EC-18 QD

Primary Outcome Measures :
  1. Rate of transition to ARDS [ Time Frame: 14 days after starting IP administration ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed informed consent
  • Male or female age 19 years or older
  • Pathologically confirmed diagnosis of COVID-19 Infection to Pneumonia

Exclusion Criteria:

  • Pathologically confirmed diagnosis of bacterial pneumonia or viral pneumonia
  • Pregnant or nursing at the time of signing informed consent
  • Known sensitivity to any study medication
  • Unwilling or unable to complete study diary
  • Any other condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with the protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04500132

Layout table for location contacts
Contact: Enzychem Lifescience 02-501-1084

Layout table for location information
Korea, Republic of
Chungbuk National University Hospital Recruiting
Cheongju-si, Korea, Republic of
Sponsors and Collaborators
Enzychem Lifesciences Corporation
Layout table for investigator information
Principal Investigator: Hyewon Jeong Chungbuk National University Hospital
Layout table for additonal information
Responsible Party: Enzychem Lifesciences Corporation Identifier: NCT04500132    
Other Study ID Numbers: EC-18-C201
First Posted: August 5, 2020    Key Record Dates
Last Update Posted: August 6, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections